Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
about
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase 2 and biomarker study of ...... s with recurrent glioblastoma.
@en
Phase 2 and biomarker study of ...... s with recurrent glioblastoma.
@nl
type
label
Phase 2 and biomarker study of ...... s with recurrent glioblastoma.
@en
Phase 2 and biomarker study of ...... s with recurrent glioblastoma.
@nl
prefLabel
Phase 2 and biomarker study of ...... s with recurrent glioblastoma.
@en
Phase 2 and biomarker study of ...... s with recurrent glioblastoma.
@nl
P2093
P2860
P356
P1433
P1476
Phase 2 and biomarker study of ...... ts with recurrent glioblastoma
@en
P2093
Alona Muzikansky
Andrew B Lassman
Daniel G Duda
Elizabeth R Gerstner
Eudocia Quant Lee
Jennifer Barrs
Jennifer Bruno
Patrick Y Wen
Rakesh K Jain
Sarah C Gaffey
P2860
P304
P356
10.1002/CNCR.31172
P407
P577
2017-12-19T00:00:00Z